CLINICAL ASPECTS OF DRUG CLASS «ERBISOL®» IN THE TREATMENT OF SOLID TUMORS

Maksymiak G.I., Chyshkevich Yu.V., Smirnov G.Yu., Mylashin O.B., Nikolayenko O.M., Zhylchuk V.E., Bezdenezhnykh N.A.

We used «ERBISOL®» which is a new and promising direction in the treatment of patients with solid tumors. We found that «ERBISOL®» can influence to the kinetics of growth of solid tumors and increase effector mechanism mediated through presentative function of macrophages and NK-cells and T-killers. The use of these drugs in combination with endolymphatic chemotherapy in patients with rectal cancer contributes to rather reparative processes in the time after the surgical procedure, increasing the frequency of clinical antitumor effect. We also found that the use of immunomodulators in combination with adjuvant chemotherapy improves totall 3-year survival in patients with gastric cancer; increases the median survival of patients with non small cell lung cancer and duration of disease stabilization in patients with unresectable and metastatic pancreatic cancer.